The Role of Optical Coherence Tomography in the Evaluation of Ocular Photodynamic Therapy

  • Caroline R. Baumal
  • Rubin W. Kim

Clinical studies in vitreoretinal disorders utilize a variety of modalities in order to assess the retina’s response to different therapies. The standard methods include visual acuity assessment, clinical examination, angiography, and electrophysiologic testing. Visual acuity is a primary outcome in most ophthalmology studies. It is measured by standardized techniques such as the Early Treatment for Diabetic Retinopathy Study (ETDRS) chart or the modified Bailey-Lovie chart. Clinical examination may involve a certified study examiner or multiple examiners and it may be performed in a masked fashion. Angiography with fluorescein dye is used to assess the posterior segment circulation. It has traditionally been the gold standard test to diagnose and classify choroidal neovascularization (CNV), as well as to evaluate the response of CNV to therapy. Indocyanine green (ICG) dye, which was originally used in cardiovascular imaging, has recently found applications in ophthalmology. The molecular and fluorescent properties of ICG permit improved imaging of the choroidal circulation. In some cases, ICG may permit evaluation of pathology, which is not visualized with fluorescein angiography due to blockage by hemorrhage. Electrophysiologic tests such as the electroretinogram (ERG) and electro-oculogram (EOG) are useful to localize pathology to a specific level or location in the retina and to monitor the effect of therapy.


Optical Coherence Tomography Retinal Pigment Epithelium Photodynamic Therapy Cystoid Macular Edema Optical Coherence Tomography Imaging 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Puliafito CA, Hee MR, Lin, CP, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217–229.PubMedGoogle Scholar
  2. 2.
    Drexler W, Sattmann H, Hermann B, et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 2003;121:695–706.PubMedCrossRefGoogle Scholar
  3. 3.
    Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 1999;117:1329–1345.Google Scholar
  4. 4.
    Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol 1995;39:367–374.PubMedCrossRefGoogle Scholar
  5. 5.
    Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Macular photocoagulation study group. Arch Ophthalmol 1994;112:489–499.Google Scholar
  6. 6.
    Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular photocoagulation study group. Arch Ophthalmol 1994;112:480–488.Google Scholar
  7. 7.
    Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular photocoagulation study group. Arch Ophthalmol 1993;111:1200–1209.Google Scholar
  8. 8.
    Verteporfin in photodynamic therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. Ophthalmology 2003;110:667–673.CrossRefGoogle Scholar
  9. 9.
    Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260–1270.PubMedGoogle Scholar
  10. 10.
    Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566–576.PubMedCrossRefGoogle Scholar
  11. 11.
    Costa RA, Farah ME, Cardillo JA, et al. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003;23:159–165.PubMedCrossRefGoogle Scholar
  12. 12.
    Rumelt S, Kaiserman I, Rehany U, et al. Detachment of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2002;134:822–827.PubMedCrossRefGoogle Scholar
  13. 13.
    Theodossiadis GP, Panagiotidis D, Georgalas IG, et al. Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003;241:13–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517–1525.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenfeld PJ, Heier JS, Chung CY, McCluskey ER. RhuFab V2 Dose-escalation trial: safety and tolerability of 3 escalating dosing regimens in subjects with age-related macular degeneration. Abstract. New York: American Society of Retina Specialists, August 2003.Google Scholar
  16. 16.
    Antoszyk AN, Sy JP, McCluskey ER, rhuFabV2 Study Group. RhuFab V2 in wet AMD: changes in OCT measures of the ocular edema. Abstract. New York: American Society of Retina Specialist, August 2003.Google Scholar
  17. 17.
    Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic serous chorioretinopathy: a pilot study. Retina 2003;23:288–298.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Caroline R. Baumal
    • 1
  • Rubin W. Kim
    • 1
  1. 1.Vitreoretinal Service, New England Eye CenterTufts University School of MedicineBoston

Personalised recommendations